Sagimet Biosciences Inc
NASDAQ:SGMT

Watchlist Manager
Sagimet Biosciences Inc Logo
Sagimet Biosciences Inc
NASDAQ:SGMT
Watchlist
Price: 6.23 USD -1.58% Market Closed
Market Cap: 200.6m USD

Relative Value

There is not enough data to reliably calculate the relative value of SGMT.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SGMT Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
22
Median 3Y
0
Median 5Y
0
Industry
7.9
vs History
vs Industry
Median 3Y
-4.1
Median 5Y
-4.1
Industry
23.7
Forward
-3.7
vs History
vs Industry
Median 3Y
-4.8
Median 5Y
-4.8
Industry
22
vs History
vs Industry
Median 3Y
-4.8
Median 5Y
-4.8
Industry
23.8
vs History
32
vs Industry
63
Median 3Y
0.9
Median 5Y
0.9
Industry
3.3
vs History
vs Industry
71
Median 3Y
0
Median 5Y
0
Industry
8.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.1
vs History
vs Industry
25
Median 3Y
0
Median 5Y
0
Industry
6.4
Forward
-1.4
vs History
vs Industry
23
Median 3Y
0
Median 5Y
0
Industry
7
Forward
-1.4
vs History
vs Industry
26
Median 3Y
0
Median 5Y
0
Industry
8.3
vs History
vs Industry
22
Median 3Y
0
Median 5Y
0
Industry
6.5
vs History
45
vs Industry
45
Median 3Y
11.6
Median 5Y
11.6
Industry
5.7

Multiples Across Competitors

SGMT Competitors Multiples
Sagimet Biosciences Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Sagimet Biosciences Inc
NASDAQ:SGMT
202.6m USD 0 -3.5 -1.3 -1.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 794 036.5 -160 618 -195 041.5 -192 815.9
US
Abbvie Inc
NYSE:ABBV
391.7B USD 6.6 166.8 16.2 23
US
Amgen Inc
NASDAQ:AMGN
170.4B USD 4.7 24.3 17.7 17.7
US
Gilead Sciences Inc
NASDAQ:GILD
148.9B USD 5.1 18.4 12.3 12.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.7B USD 9.8 31.2 22.9 23.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 084.7 -531.9 -579.2 -563.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.9B USD 5.5 17 16.2 18.3
AU
CSL Ltd
ASX:CSL
89.1B AUD 3.8 19.8 13.3 16.5
NL
argenx SE
XBRU:ARGX
46.1B EUR 15 35.3 61 62.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
51.4B USD 16 1 180.4 154.9 187.9
P/S Multiple
Revenue Growth P/S to Growth
US
Sagimet Biosciences Inc
NASDAQ:SGMT
Average P/S: 3 379 618.8
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 794 036.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
5%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
5.1
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
10%
1
US
E
Epizyme Inc
F:EPE
2 084.7
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
6%
0.9
AU
CSL Ltd
ASX:CSL
3.8
5%
0.8
NL
argenx SE
XBRU:ARGX
15
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16
46%
0.3
P/E Multiple
Earnings Growth PEG
US
Sagimet Biosciences Inc
NASDAQ:SGMT
Average P/E: 186.7
Negative Multiple: -3.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 618 N/A N/A
US
Abbvie Inc
NYSE:ABBV
166.8
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.3
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.4
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.2
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
9%
1.9
AU
CSL Ltd
ASX:CSL
19.8
11%
1.8
NL
argenx SE
XBRU:ARGX
35.3
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 180.4
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Sagimet Biosciences Inc
NASDAQ:SGMT
Average EV/EBITDA: 39.3
Negative Multiple: -1.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 041.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.2
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.7
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.9
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
11%
1.5
AU
CSL Ltd
ASX:CSL
13.3
8%
1.7
NL
argenx SE
XBRU:ARGX
61
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
154.9
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Sagimet Biosciences Inc
NASDAQ:SGMT
Average EV/EBIT: 45.3
Negative Multiple: -1.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 815.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.7
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.3
13%
1.4
AU
CSL Ltd
ASX:CSL
16.5
11%
1.5
NL
argenx SE
XBRU:ARGX
62.7
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
187.9
N/A N/A